Deep vein thrombosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Deep vein thrombosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the use of colchicine to reduce inflammation in patients with deep vein thrombosis. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-use-of-colchicine-to-reduce-inflammation-in-patients-with-deep-vein-thrombosis/ Wed, 29 Apr 2026 15:10:06 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-use-of-colchicine-to-reduce-inflammation-in-patients-with-deep-vein-thrombosis/ This study focuses on Deep Vein Thrombosis, a condition where a blood clot forms in a deep vein, typically in the legs. A common long-term complication of this condition is Post-thrombotic syndrome, which is a set of symptoms like swelling, pain, and skin changes that can occur after the clot has been treated. The purpose of the study is to evaluate if taking a low dose of colchicine can help reduce the risk of developing this syndrome.

Participants in the study will be assigned to receive either a 0.5 mg tablet of colchicine once a day or a placebo once a day. The study will monitor participants over a period of time to observe the effects of the medication on their health and to check for any possible side effects. This process involves tracking various health outcomes to see how the treatment compares to the inactive pill.

]]> Study on Apixaban for Preventing Blood Clots in Leg Veins During Long-Distance Flights for Travelers at Risk https://clinicaltrials.eu/trial/study-on-apixaban-for-preventing-blood-clots-in-leg-veins-during-long-distance-flights-for-travelers-at-risk/ Wed, 29 Apr 2026 15:05:37 +0000 https://clinicaltrials.eu/trial/study-on-apixaban-for-preventing-blood-clots-in-leg-veins-during-long-distance-flights-for-travelers-at-risk/ This clinical trial is focused on studying the prevention of blood clots, specifically leg vein thrombosis, which can occur during long-distance flights. The trial will use a medication called Apixaban, which is taken in the form of a 2.5 mg film-coated tablet. The purpose of the study is to determine if taking a single dose of Apixaban can significantly reduce the risk of developing leg vein thrombosis during long-haul flights.

Participants in the study will be given either the Apixaban tablet or a placebo, which looks like the real medication but does not contain the active ingredient. The study will involve taking the medication before the outbound flight and again before the return flight. The trial aims to observe the occurrence of any clinically relevant leg vein thrombosis during these flights.

The study will also monitor for any bleeding events, as this is a potential side effect of taking Apixaban. The trial is expected to run until 2028, with recruitment starting in 2026. This research is important for understanding how to prevent blood clots in people who travel long distances by air, which can be a risk factor for developing such conditions.

]]> Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism https://clinicaltrials.eu/trial/study-on-rosuvastatin-for-reducing-blood-clots-in-patients-with-deep-vein-thrombosis-or-pulmonary-embolism/ Wed, 29 Apr 2026 14:30:35 +0000 https://clinicaltrials.eu/trial/study-on-rosuvastatin-for-reducing-blood-clots-in-patients-with-deep-vein-thrombosis-or-pulmonary-embolism/ This clinical trial is focused on studying the effects of a medication called Rosuvastatin Calcium in patients who have experienced certain types of blood clots. The diseases being studied include Pulmonary Embolism, Venous Thromboembolism, and Deep Vein Thrombosis. These conditions involve the formation of blood clots in the veins, which can be serious and require medical attention. The trial will compare the effects of Rosuvastatin Calcium to a placebo, which is a substance with no active medication, to see if the medication can help reduce the occurrence of these blood clots.

The purpose of the study is to determine if taking Rosuvastatin Calcium can lower the rate of major blood clot events in patients who have already had a clot. Participants in the study will be randomly assigned to receive either Rosuvastatin Calcium or a placebo. The study will monitor the participants over a period of time to observe any differences in the recurrence of blood clots between the two groups. The trial will also look at other health outcomes, such as the development of post-thrombotic syndrome, which is a condition that can occur after a blood clot, and other vascular events like heart attacks or strokes.

Throughout the study, participants will be regularly checked to ensure their safety and to gather information on how the medication is affecting their health. The trial is expected to continue until the end of 2027, providing valuable insights into the potential benefits of Rosuvastatin Calcium for patients with these types of blood clots.

]]> Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-3018250-and-low-molecular-weight-heparin-for-patients-with-proximal-deep-vein-thrombosis/ Wed, 29 Apr 2026 14:26:19 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-3018250-and-low-molecular-weight-heparin-for-patients-with-proximal-deep-vein-thrombosis/ This clinical trial is focused on studying a condition known as proximal deep vein thrombosis (DVT), which is a type of blood clot that forms in the deep veins, usually in the legs. The study is investigating a treatment called BAY 3018250, which is a concentrate for solution for infusion. This means it is a liquid form of medication that is given through a needle into a vein. The trial will also involve a comparison with a placebo solution to help understand the effects of the treatment.

The purpose of the study is to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over a period of time. The study will look at how the treatment affects the blood clot and any side effects that may occur. The trial will also involve the use of low molecular weight heparin, a type of medication that helps prevent blood clots, given by injection under the skin.

Throughout the study, participants will have regular check-ups to assess the size of the blood clot and any changes in symptoms, such as leg pain. These assessments will be done using ultrasound, a method that uses sound waves to create images of the inside of the body. The study will last for several months, with follow-up visits to monitor the participants’ health and the effectiveness of the treatment. The goal is to provide valuable information that could lead to better treatment options for people with proximal deep vein thrombosis.

]]> Study on Dabigatran, Apixaban, Rivaroxaban, and Edoxaban for Patients with Atrial Fibrillation, Deep Vein Thrombosis, or Pulmonary Embolism https://clinicaltrials.eu/trial/study-on-dabigatran-apixaban-rivaroxaban-and-edoxaban-for-patients-with-atrial-fibrillation-deep-vein-thrombosis-or-pulmonary-embolism/ Wed, 29 Apr 2026 14:25:05 +0000 https://clinicaltrials.eu/trial/study-on-dabigatran-apixaban-rivaroxaban-and-edoxaban-for-patients-with-atrial-fibrillation-deep-vein-thrombosis-or-pulmonary-embolism/ This clinical trial is focused on studying the effects of four different medications on patients with certain heart and blood conditions. The diseases being studied include Atrial Fibrillation (a condition where the heart beats irregularly), Deep Vein Thrombosis (a blood clot in a deep vein, usually in the legs), and Pulmonary Embolism (a blockage in one of the pulmonary arteries in the lungs). The medications being tested are Dabigatran Etexilate, Apixaban, Rivaroxaban, and Edoxaban. These medications are known as non-vitamin K antagonist oral anticoagulants (NOACs), which help prevent blood clots.

The purpose of the study is to compare these four medications to see how safe and effective they are in preventing death and hospitalizations without increasing the risk of major bleeding. The study will involve patients who have been diagnosed with atrial fibrillation, deep vein thrombosis, or pulmonary embolism. Participants will receive one of the four medications or a placebo, and their health will be monitored over time to assess the outcomes.

Throughout the study, participants will take the medication orally, as prescribed, and will be regularly checked by healthcare professionals. The study aims to provide valuable information on whether these medications are equally effective and safe for patients with the specified conditions. The trial is expected to continue until 2027, allowing for comprehensive data collection and analysis.

]]> Study on the Best Antithrombotic Therapy for Patients with Acute Venous Thromboembolism Using Tinzaparin Sodium and Drug Combination https://clinicaltrials.eu/trial/study-on-the-best-antithrombotic-therapy-for-patients-with-acute-venous-thromboembolism-using-tinzaparin-sodium-and-drug-combination/ Wed, 29 Apr 2026 14:24:37 +0000 https://clinicaltrials.eu/trial/study-on-the-best-antithrombotic-therapy-for-patients-with-acute-venous-thromboembolism-using-tinzaparin-sodium-and-drug-combination/ This clinical trial is focused on studying the best treatment options for patients with acute venous thromboembolism (VTE), a condition where blood clots form in the veins, often in the legs, and can travel to the lungs, causing a blockage known as a pulmonary embolism. The study will compare the effectiveness of using full-dose anticoagulant therapy alone versus combining it with antiplatelet therapy. Anticoagulants are medications that help prevent blood clots, while antiplatelets are used to prevent blood cells called platelets from clumping together, which can also lead to clots.

The medications being studied include INNOHEP (tinzaparin sodium), COUMADINE (warfarin sodium), Eliquis (apixaban), FRAGMINE (dalteparin sodium), Arixtra (fondaparinux sodium), SINTROM (acenocoumarol), HEPARINE CHOAY (heparin sodium), KARDEGIC (d,l-lysine acetylsalicylate), CALCIPARINE (heparin calcium), LOVENOX (enoxaparin sodium), Xarelto (rivaroxaban), and Plavix (clopidogrel). Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The purpose of the study is to determine if using full-dose anticoagulant therapy alone reduces the risk of significant bleeding compared to using it in combination with antiplatelet therapy. Participants will be monitored for up to 12 months to assess the occurrence of bleeding and other related health events. The study aims to provide insights into the safest and most effective treatment approach for patients with acute VTE who are also taking antiplatelet medications for other heart-related conditions.

]]>